Global InformationProsensa information
 | This article uses bare URLs, which are uninformative and vulnerable to link rot. (September 2022) |
| Company type | Public |
|---|---|
Traded as | Nasdaq: RNA |
| Industry | Biotechnology |
| Founded | 2002 |
| Headquarters | Leiden, Netherlands |
Key people | Hans Schikan (CEO), Berndt Modig (CFO), Giles Champion (CMO), Luc Dochez (CBO) David Mott (Chairman) |
| Products | Pharmaceuticals |
Number of employees | 89 (2014) |
| Website | www.prosensa.com |
Prosensa was a biotechnology company engaged in the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne muscular dystrophy (DMD), myotonic dystrophy, and Huntington's disease. Prosensa was acquired by BioMarin [1]
- ^ http://investors.bmrn.com/releasedetail.cfm?releaseid=884456